TEMPORAL LOBE HERNIATION AND CHIASMOPATHY DURING DOPAMINE AGONIST THERAPY FOR PROLACTINOMA. [PDF]
Acta Endocrinol (Buchar), 2023 Giraldi EA +4 more
europepmc +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background The magnitude and factors associated with levodopa equivalent daily dose (LEDD) reduction in deep brain stimulation (DBS) of the globus pallidus interna (GPi) for Parkinson's Disease (PD) remain unclear. Objective To investigate LEDD reduction in GPi DBS and its correlation with anatomical/clinical characteristics.
Daniel G. Di Luca +7 more
wiley +1 more source
Agonist-Antagonist Pouch Motors: Bidirectional Soft Actuators Enhanced by Thermally Responsive Peltier Elements [PDF]
In this study, we introduce a novel Mylar-based pouch motor design that leverages the reversible actuation capabilities of Peltier junctions to enable agonist-antagonist muscle mimicry in soft robotics. Addressing the limitations of traditional silicone-based materials, such as leakage and phase-change fluid degradation, our pouch motors filled with ...
arxiv +1 more source
Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy. [PDF]
Front Endocrinol (Lausanne), 2023 Wang L, Wang X, Gong F, Pan H, Zhu H.
europepmc +1 more source
Differential effects of dopamine agonists upon stimulated limbic and striatal dopamine release: in vivo voltammetric data [PDF]
, 1991 Jonathan A. Stamford +2 more
openalex +1 more source
Evidence of Involvement of the Calcitonin Gene‐Related Peptide in Restless Legs Syndrome
Movement Disorders, EarlyView.Abstract Background Restless legs syndrome (RLS) is a common sensory‐motor disorder characterized by an urge to move the legs, often with unpleasant sensations, particularly during rest. Current treatments include iron supplementation, dopamine agonists, and opioids, but new therapeutic approaches are needed.
Maria P. Mogavero +8 more
wiley +1 more source
Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia. [PDF]
Mov Disord, 2023 Espa E +4 more
europepmc +1 more source
Regulation of aromatic
, 1994 Meng‐Yang Zhu +3 more
openalex +1 more source
Movement Disorders, EarlyView.Abstract Background The substantia nigra (SN) and locus coeruleus (LC) are among the first brain regions to degenerate in Parkinson's disease (PD). This has important implications for early cognitive deficits because these nuclei are sources of ascending neuromodulators (i.e., dopamine and noradrenaline) that support various cognitive functions such as
Sophie Sun +6 more
wiley +1 more source
Finely Tuned γ Tracks Medication Cycles in Parkinson's Disease: An Ambulatory Brain‐Sense Study
Movement Disorders, EarlyView.Abstract Background Novel commercial brain‐sense neurostimulators enable us to contextualize brain activity with symptom and medication states in real‐life ambulatory settings in Parkinson's disease (PD). Although various candidate biomarkers have been proposed for adaptive deep brain stimulation (DBS), a comprehensive comparison of their ambulatory ...
Aaron Colombo +17 more
wiley +1 more source